Document Detail

Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking.
MedLine Citation:
PMID:  15194015     Owner:  NLM     Status:  MEDLINE    
A polymorphism of glycoprotein IIb/IIIa has been associated with myocardial infarction and restenosis after percutaneous coronary intervention. The influence on outcome and the interaction of the Pl(A1) genotype with classic risk factors for coronary artery disease (CAD) were characterized in patients with chronic CAD followed prospectively for 3 years. Pl(A1) genotypes were assessed in 592 patients enrolled in the Medical, Angioplasty, or Surgery Study II, a randomized trial comparing treatments for patients with CAD and preserved left ventricular function. The incidence of the composite end point of cardiac death, myocardial infarction, and refractory angina requiring revascularization were determined in each genotype group. Risk was assessed with the Cox proportional-hazards model. The clinical characteristics and treatment of each genotype were similar. Although the composite end point tended to be more common in patients with the Pl(A2) allele, only smokers with the Pl(A2) allele had a significantly increased incidence of the composite end point (p = 0.01). Moreover, a 2.2-fold increased risk was apparent in smokers with the Pl(A2) allele (p = 0.03). Thus, taken together, these data provide support for the interaction effect between smoking and the Pl(A1) gene variant. Smokers with the Pl(A2) polymorphism of platelet glycoprotein IIIa are at greater risk for subsequent cardiac events in stable coronary disease.
Neuza H M Lopes; Alexandre C Pereira; Whady Hueb; Paulo R Soares; Jose R Lanz; Bernard J Gersh; Sergio de Oliveira; Luiz A M Cesar; Jose F Ramires; Jose Eduardo Krieger
Related Documents :
16408115 - Mild renal insufficiency is associated with reduced coronary flow in patients with non-...
1444685 - Occupation and risk of nonfatal myocardial infarction.
19804285 - Potential of adiponectin as a cardioprotective agent.
22050785 - Natural history of prenatal ventricular septal defects and their association with foeta...
2674435 - The effects of angiotensin-converting enzyme inhibition on coronary blood flow and infa...
22430385 - Stem cell therapy for cardiac disease.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  93     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-14     Completed Date:  2004-07-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1469-72     Citation Subset:  AIM; IM    
Heart Institute (InCor) of the University of São Paulo, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina Pectoris / genetics
Coronary Artery Disease / genetics*,  mortality
Middle Aged
Myocardial Infarction / genetics
Myocardial Revascularization
Platelet Glycoprotein GPIIb-IIIa Complex / genetics*
Polymorphism, Genetic*
Proportional Hazards Models
Prospective Studies
Risk Factors
Smoking / adverse effects*
Reg. No./Substance:
0/Platelet Glycoprotein GPIIb-IIIa Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute...
Next Document:  The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of eth...